Soluble elotuzumab F(ab′)2 alone or in combination with lenalidomide failed to mediate myeloma cell killing (Fig. 3c) and induce certain NK cell activation markers (CD25 and CD54 expression) in the co-culture model examined (Fig. 3d). The gene discussed is ICAM1; the disease is plasma cell myeloma.